Based in the United States, ImmunoVec is a startup.
ImmunoVec develops in vivo therapies to precisely engineer targeted cell types within the human body using cell type- and state-specific transcriptional control elements applicable across viral and non-viral delivery platforms.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.